| 于丽华,王宏,秦丽,张冬梅,崔东燕,赵书平.Pygo2、M2BPGi在慢性乙型肝炎肝纤维化患者血清中的表达及联合诊断价值.[J].中南医学科学杂志.,2021,(2):197-202. |
| Pygo2、M2BPGi在慢性乙型肝炎肝纤维化患者血清中的表达及联合诊断价值 |
| Expression of serum Pygo2 and M2BPGi in patients with chronic hepatitis B hepatic fibrosis and its combined diagnostic value |
| |
| DOI：10.15972/j.cnki.43-1509/r.2021.02.016 |
| 中文关键词: 慢性乙型肝炎 肝纤维化 人尾肢同源蛋白2 Mac-2结合蛋白糖基化异构体 诊断效能 [ |
| 英文关键词:chronic hepatitis B hepatic fibrosis human pygopus homolog 2 Mac-2 binding protein glycosylation isomer diagnostic efficacy |
| 基金项目: |
|
| 摘要点击次数: 523 |
| 全文下载次数: 326 |
| 中文摘要: |
| 目的研究人尾肢同源蛋白2(Pygo2)、Mac-2结合蛋白糖基化异构体(M2BPGi)在慢性乙型肝炎肝纤维化患者中的诊断效能。 方法选取345例慢性乙型肝炎患者,根据病理活检肝纤维化分期结果,将患者分别纳入S0组(n＝49)、S1组(n＝94)、S2组(n＝53)、S3组(n＝87)及S4组(n＝62)。应用全自动酶标仪酶联免疫法检测血清Pygo2和M2BPGi水平,应用ROC曲线分析血清Pygo2和M2BPGi单独及联合检测预测慢性乙型肝炎肝纤维化分期的诊断效能。 结果检测血清Pygo2诊断S1的临界值为62.35 μg/L,灵敏度为79.73%,特异度为79.76%,药时曲线下面积(AUC)为0.826(95%CI 0.774~0.877)；检测血清M2BPGi诊断S1的临界值为0.74 g/L,灵敏度为79.39%,特异度为76.78%,AUC为0.784(95%CI 0.758~0.810)。平行联合检测诊断S1的灵敏度为90.20%,特异度为73.21%,AUC为0.903(95%CI 0.804~0.918)。检测血清Pygo2诊断S2的临界值为78.65 μg/L,灵敏度为82.67%,特异度为79.39%,AUC为0.829(95%CI 0.779~0.867)；检测血清M2BPGi诊断S2的临界值为1.01 g/L,灵敏度为79.70%,特异度为78.62%,AUC为0.793(95%CI 0.763~0.815)。平行联合检测诊断S2的灵敏度为90.59%,特异度为77.48%,AUC为0.908(95%CI 0.799~0.919)。 结论血清Pygo2和M2BPGi单独检测对慢性乙型肝炎肝纤维化临床诊断具有重要意义,且平行联合检测可提高肝纤维化诊断效能。 |
| 英文摘要: |
| To study the diagnostic efficacy of human tail limb homologous protein 2 (Pygo2) and Mac-2 binding protein glycosylated isomer (M2BPGi) in chronic hepatitis B (CHB) patients with hepatic fibrosis. Methods345 patients with chronic hepatitis B were selected, and according to the results of pathological biopsy of hepatic fibrosis, the patients were included in the S0 group (n＝49), S1 group (n＝94), S2 group (n＝53), S3 group (n＝87), and S4 group (n＝62). The automatic microplate reader enzyme-linked immunosorbent assay was used to detect serum Pygo2 and M2BPGi level indicators, and ROC curve analysis was used to analyze the serum Pygo2 and M2BPGi indicators alone and combined to predict the diagnostic efficacy of chronic hepatitis B hepatic fibrosis staging. ResultsThe critical value of serum Pygo2 for diagnosis of S1 was 62.35 μg/L, the sensitivity was 79.73%, the specificity was 79.76%, and the area under drug time curve (AUC) was 0.826 (95%CI 0.774－0.877); the critical value of serum M2BPGi for diagnosis of S1 was 0.74 g/L, the sensitivity was 79.39%, the specificity was 76.78%, and the AUC was 0.784 (95%CI 0.758－0.810). The sensitivity, specificity and AUC of combined detection were 90.20%, 73.21% and 0.903 (95%CI 0.804－0.918). The cut-off value of Pygo2 was 78.65 μg/L, sensitivity was 82.67%, specificity was 79.39%, AUC was 0.829 (95%CI 0.779－0.867); the cut-off value of M2BPGi was 1.01 g/L, sensitivity was 79.70%, specificity was 78.62%, AUC was 0.793 (95%CI 0.763－0.815). The sensitivity, specificity and AUC of combined detection were 90.59%, 77.48% and 0.908 respectively (95%CI 0.799－0.919). ConclusionThe detection of serum Pygo2 and M2BPGi alone is of great significance in the clinical diagnosis of hepatic fibrosis, and parallel combined detection can improve the diagnostic sensitivity of hepatic fibrosis and provide a rapid, convenient and accurate method for the early diagnosis of hepatic fibrosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|